Obermatt
See Similar Stocks →

Tonix Pharmaceuticals

NAQ:TNXP · US8902608392
BiotechnologySmall

360

37
Profit price5
Owner Earnings Yield1
Dividend Yield1
Price/Sales75
Price/Book70
Return on Capital33
Cash Return on Capital59
Return on Equity43
Profit margins56
Accruals42
Owner Earnings Margin34
Sales growth88
Profit growth34
Reinvestment89
Price momentum4
Debt load85
Refinancing17
Debt Payback1
Liquidity6
Analyst ratings100
Expectations trend98
Market mood44
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Tonix Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Employees123
Websitetonixpharma.com
ISINUS8902608392
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyNeurologyInfectious DiseasesObesityPsychiatryPain ManagementVaccinesCentral Nervous SystemOncologyBiopharmaBiotechnologyMedicalPharmaceutical

Description

Tonix Pharmaceuticals Holding Corp. (Tonix) develops and commercializes therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. The company's portfolio consists of both commercial and development-stage pro…

Analysis

Middle-of-the-road

Tonix Pharmaceuticals Holding Corp. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 4/20 on our value-creation score: not creating value.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
38
2026

All-time high

42

Mar 2026

All-time low

38

Jun 2026

Average rank

40

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
75
—
—
—
Price/Earnings
23
—
—
—
Price/Book
70
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
53
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Tonix Pharmaceuticals with its peers
Vaxcyte
NSQ:PCVX
54
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xenon Pharmaceuticals
NMQ:XENE
28
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vera Therapeutics
NMQ:VERA
44
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Incyte
NSQ:INCY
95
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →